Hochschulschrift
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Erscheinungsjahr an der Haupttitelstelle: 2004
München, Techn. Univ., Diss., 2005
- Keyword
-
Krebs
Onkologie
Biopharmazie
Pharmakodynamik
Pharmakokinetik
- Creator
- URN
-
urn:nbn:de:bvb:91-diss2005012705592
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
Other Objects (12)
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Role of plasminogen activator inhibitor-2 (PAI-2) in acute and chronic kidney disease
Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
Pai
Plasminogen activator inhibitor (PAI-1) gene polymorphism (4G/5G) and hepatocellular carcinoma in Egyptian patients
Bedeutung des Plasminogen-Aktivator-Inhibitors PAI-1 und des binding Proteins PAI-RBP1 beim epithelialen Ovarialkarzinom
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Einfluss von Biopsie-, Aufarbeitungs- und Asservierungsbedingungen auf den Nachweis von urokinase type plasminogen activator (uPA) und plasminogen activator inhibitor-1 (PAI-1) beim Mammakarzinom
Sin pai
PAiN
PAiN
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Role of plasminogen activator inhibitor-2 (PAI-2) in acute and chronic kidney disease
Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
Pai
Plasminogen activator inhibitor (PAI-1) gene polymorphism (4G/5G) and hepatocellular carcinoma in Egyptian patients
Bedeutung des Plasminogen-Aktivator-Inhibitors PAI-1 und des binding Proteins PAI-RBP1 beim epithelialen Ovarialkarzinom
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Einfluss von Biopsie-, Aufarbeitungs- und Asservierungsbedingungen auf den Nachweis von urokinase type plasminogen activator (uPA) und plasminogen activator inhibitor-1 (PAI-1) beim Mammakarzinom
Sin pai
PAiN
PAiN
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Role of plasminogen activator inhibitor-2 (PAI-2) in acute and chronic kidney disease
Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
Pai
Plasminogen activator inhibitor (PAI-1) gene polymorphism (4G/5G) and hepatocellular carcinoma in Egyptian patients
Bedeutung des Plasminogen-Aktivator-Inhibitors PAI-1 und des binding Proteins PAI-RBP1 beim epithelialen Ovarialkarzinom
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Einfluss von Biopsie-, Aufarbeitungs- und Asservierungsbedingungen auf den Nachweis von urokinase type plasminogen activator (uPA) und plasminogen activator inhibitor-1 (PAI-1) beim Mammakarzinom
Sin pai
PAiN